Fox Business - The Power to Prosper
Search Site

Novartis

Pfizer takes its shot at a vaccine for evasive superbug

Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.Jansen's next vaccine success could come by taming the superbug MRSA, a drug-resistant bacterium that she has seen ravage a healthy man up close and personally.Methicillin-resistant Staphylococcus aureus infects an estimated 53 million people globally and costs more than $20 billion a year to treat. In the United States alone, MRSA kills 20,000 Americans each year, exceeding annual deaths from AIDS.Jansen watched the infection unfold two years ago when visiting her stepfather, who was in the hospital for a hip replacement. The man in the bed next door died soon after MRSA attacked the vascular graft in his leg."He went in healthy and died very quickly," recalls Jansen, senior vice president of vaccine research and early development at Pf...

Read More

  1. Endo Health Swings to First-Quarter Profit On Strong Generic Drug Sales

    Endo Health Solutions Inc. (ENDP) swung to a first-quarter profit amid fewer write-downs and other items, as well as a modest revenue increase as strong sales growth...

  2. Auction of Brazilian Drug Company Ache Stalls on Differences Among Family Owners -Sources

    The auction of AchÛ LaboratÛrios FarmacÛuticos SA, which has drawn interest from some of the biggest names in the global healthcare industry, has stalled due to disa...

  3. U.S. Sues Novartis Over Drug Kickbacks

    U.S. federal prosecutors filed a lawsuit against Novartis Pharmaceuticals, accusing the company of paying kickbacks to doctors in an effort to encourage prescription...

  4. U.S. Sues Novartis for Allegedly Paying Kickbacks

    Federal prosecutors accused Novartis Pharmaceuticals Corp. of paying kickbacks and providing lavish dinners to doctors to encourage them to prescribe the company's b...

  5. U.S. Sues Novartis Over Drug Kickbacks

    The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multi-milli...

  6. U.S. files second lawsuit accusing Novartis of kickbacks

    The government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multi-million do...

  7. Mixed Results for Drug Companies

    AstraZeneca PLC (AZN.LN) said Thursday profit and sales fell for a fifth-consecutive quarter as the drug giant continues to suffer patent expiries that leave some of...

  8. Novartis Boosted by Drug Launches

    Swiss drug maker Novartis AG (NOVN.VX) Wednesday posted a rise in first-quarter net profit, as new product launches and strength in emerging markets helped offset de...

  9. U.S. Lawsuit Alleges Healthcare Fraud By Novartis

    Federal prosecutors late Tuesday accused Novartis Pharmaceuticals Corp. of bribing pharmacies to switch kidney patients from generic drugs to the company's own produ...

  10. Novartis 1Q Net Profit Misses Expectations; New Products Deliver

    Swiss drug maker Novartis AG (NVS) on Wednesday posted a worse-than-expected first-quarter net profit. This is in spite of new product launches and sales in emerging...

  11. U.S. Accuses Novartis Of Kickbacks

    Federal prosecutors accused Novartis Pharmaceuticals Corp. of paying kickbacks to get pharmacies to switch kidney-transplant patients from generic drugs to the compa...

  12. U.S. Accuses Novartis of Paying Kickbacks to Pharmacies in Lawsuit

    The U.S. Justice Department has accused a Novartis AG (NVS) pharmaceutical division of providing kickbacks to pharmacies to switch patients to a Novartis drug used t...

  1. Actavis to Buy Warner Chilcott for $5 Billion in Stock

    Drug maker Actavis Inc. (ACT) agreed to acquire Warner Chilcott PLC (WCRX) for about $5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specia...

  2. Actavis to Buy Warner Chilcott For $5 Billion in Stock

    Drug maker Actavis Inc. (ACT) agreed to acquire Warner Chilcott PLC (WCRX) for about $5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specia...

  3. Affymetrix Names Gavin Wood Chief Financial Officer

    Affymetrix Inc. (AFFX) named Gavin Wood chief financial officer and executive vice president to succeed Tim Barabe, who intends to retire June 28.Mr. Wood joined Aff...

  4. Novartis Considers Possible Bid for Actavis

    A heated takeover battle has erupted around generic-drug company Actavis Inc. (ACT) as industry players seek to shore themselves up amid increasing competition and f...

  5. Analysis: Drugmakers face more scrutiny of discordant U.S. prices

    The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end.Companies like Pfizer...

  6. Novartis : FDA Approves Ilaris for Serious Form of Childhood Arthritis

    Novartis AG (NVS, NOVN.VX) said the U.S. Food and Drug Administration approved Ilaris for the treatment of active systemic juvenile idiopathic arthritis, a serious f...

  7. Merck sales rep claims sexual bias, seeks over $100 million

    A senior sales representative for Merck & Co has sued the drugmaker for more than $100 million, alleging it discriminates against female employees in terms of pay an...

‹ Prev12345Next ›
Freebase CC-BY
Source: Novartis on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL